Menta Capital’s Pacira BioSciences PCRX Stock Holding History

Menta Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-15,400	Closed	-$497K	–	943
2016 Q4	$497K	Buy	+15,400	New	+$514K	0.04%	625
2015 Q2	–	Sell	-4,400	Closed	-$391K	–	742
2015 Q1	$391K	Buy	4,400 +2,000	+83%	+$203K	0.05%	512
2014 Q4	$213K	Buy	+2,400	New	+$227K	0.03%	595
2014 Q3	–	Sell	-6,300	Closed	-$579K	–	652
2014 Q2	$579K	Buy	+6,300	New	+$480K	0.11%	262

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Menta Capital's PCRX Position: Q1 2017 in Review

Menta Capital sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 15,400 shares — an estimated $497K sold.

Menta Capital first reported a position in PCRX in Q2 2014 and held it in 4 quarters. The position peaked at $579K in Q2 2014. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

Menta Capital reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
Menta Capital sold 15,400 Pacira BioSciences shares in Q1 2017, an estimated $497K.
Menta Capital first reported a position in Pacira BioSciences in Q2 2014 and held it in 4 quarters.
Menta Capital's Pacira BioSciences position peaked at $579K in Q2 2014.
192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on Menta Capital's 13F filing for Q1 2017, filed 12 May 2017.